QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

$134.42
-1.87 (-1.37%)
(As of 02/8/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Neurocrine Biosciences Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 24 Analyst Ratings

Analysts' Consensus Price Target

$136.69
1.69% Upside
High Forecast$165.00
Average Forecast$136.69
Low Forecast$100.00
TypeCurrent Forecast
2/8/23 to 2/8/24		1 Month Ago
1/9/23 to 1/9/24		3 Months Ago
11/10/22 to 11/10/23		1 Year Ago
2/8/22 to 2/8/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
18 Buy rating(s)
17 Buy rating(s)
16 Buy rating(s)
10 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$136.69$133.32$131.46$123.06
Predicted Upside1.69% Upside19.80% Upside21.68% Upside14.99% Upside
Get Neurocrine Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.


NBIX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NBIX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Neurocrine Biosciences Stock vs. The Competition

TypeNeurocrine BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.67
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside-0.81% Downside967.15% Upside9.05% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$141.00 ➝ $140.00+5.11%
2/8/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$116.00 ➝ $140.00+4.38%
2/8/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$127.00 ➝ $140.00+2.72%
1/25/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$134.00 ➝ $153.00+9.20%
1/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$145.00 ➝ $150.00+7.30%
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$141.00 ➝ $144.00+19.73%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$136.00+14.76%
12/7/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$150.00+23.68%
11/10/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetSector Perform ➝ Sector Perform$128.00 ➝ $121.00+12.74%
11/10/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Perform ➝ Market Perform$111.00 ➝ $100.00-7.03%
11/1/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$95.00 ➝ $100.00-9.89%
11/1/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$135.00 ➝ $145.00+30.70%
10/24/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight
10/8/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$137.00 ➝ $143.00+25.52%
10/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target$125.00 ➝ $135.00+17.09%
10/6/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$152.00 ➝ $157.00+36.17%
10/6/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$160.00 ➝ $165.00+43.10%
10/6/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$146.00 ➝ $150.00+30.10%
9/13/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$133.00 ➝ $134.00+15.43%
9/13/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$120.00 ➝ $137.00+18.01%
8/21/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$123.00+15.00%
8/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$130.00+24.83%
7/24/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeMarket Perform ➝ Outperform$115.00 ➝ $125.00+26.53%
5/4/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$145.00+47.03%
4/4/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$137.00 ➝ $125.00+23.93%
3/3/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeIn-Line ➝ Outperform$130.00+29.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:17 PM ET.












NBIX Price Target - Frequently Asked Questions

What is Neurocrine Biosciences's consensus rating and price target?

According to the issued ratings of 24 analysts in the last year, the consensus rating for Neurocrine Biosciences stock is Moderate Buy based on the current 6 hold ratings and 18 buy ratings for NBIX. The average twelve-month price prediction for Neurocrine Biosciences is $136.69 with a high price target of $165.00 and a low price target of $100.00. Learn more on NBIX's analyst rating history.

Do Wall Street analysts like Neurocrine Biosciences more than its competitors?

Analysts like Neurocrine Biosciences more than other Medical companies. The consensus rating score for Neurocrine Biosciences is 2.75 while the average consensus rating score for medical companies is 2.67. Learn more on how NBIX compares to other companies.

Does Neurocrine Biosciences's stock price have much upside?

According to analysts, Neurocrine Biosciences's stock has a predicted upside of 17.95% based on their 12-month stock forecasts.

What analysts cover Neurocrine Biosciences?

Neurocrine Biosciences has been rated by Barclays, BMO Capital Markets, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, Mizuho, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:NBIX) was last updated on 2/8/2024 by MarketBeat.com Staff

My Account -